Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer

NCT04021069 is registered in ClinicalTrials.gov with Sunnybrook Health Sciences Centre as lead sponsor.

NCT NCT04021069
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04021069 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Using Clinicopathomic Markers to Predict Neoadjuvant Chemotherapy Response in Breast Cancer
Lead sponsor
Sunnybrook Health Sciences Centre
Phase
Observational
Overall status
Unknown status
Start date
August 30, 2018
Completion date
August 30, 2024
Enrollment
800 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, invasive ductal breast carcinoma, invasive lobular breast carcinoma